• Dion Morton

    Professor, MBChB, FRCS (Eng), MD, Academic Department of Surgery, Institute of Cancer and Genomic Sciences, University of Birmingham

    Dion is Director of the West Midlands Genomic Medicine Centre (WMGMC) which is a partnership of 18 NHS acute Trusts across the region, working collaboratively to help to deliver the NHS England innovative 100,000 Genomes Project. It is one of 13 similar centres, paving the way for the future of medical science - personalised medicine.   Dion also leads the Pan Cancer Genomics England Clinical Interpretation Partnership (GeCIP) and is a member of the Colorectal Cancer GeCIP. He has been Chair of the Research Committee of the European Society of Coloproctology (ESCP) since 2011 and initiated the expansion of the clinical research portfolio and growth in international collaboration within the European colorectal community. Dion has led the Birmingham Experimental Cancer Medicine Centre since 2009 leading the successful increased multi million pound refunding in 2012 and again in 2016.  The Birmingham ECMC aims to improve the feasibility and quality of research in the areas of immunotherapy and gene therapy, translational genetics and biomarkers.  It is UK government and Cancer Research UK funded and the largest centre in the UK. In 2011 he was appointed Director of Clinical Research at the Royal College of Surgeons of England and led the new Clinical Research Initiative.  The programme is now well established and has 7 Surgical Trials Units and 11 Surgical Specialty Leads (including Mr Simon Bach and BiSTC at the University). This initiative has led to the big rise in patients recruited to surgical trials and of surgical trials opened in the UK.  He is Past President of the Society for Academic and Research Surgery. Professor Morton recognised the immense potential of surgical trainees in research, and championing the development of the UK’s first trainee-led research network, the West Midlands Research Collaborative (WMRC) which pioneered a UK wide network of 18 collaboratives.

    Speaker for following sessions
    • Chemotherapy: Adjuvant treatment option for the patient with colon cancer. Is neoadjuvant treatment for the colon cancer ‘prime-time’?
      14:30:00 - 14:55:00 Carstensen
      The prospective randomized clinical trial: The UK Perspective
      15:50:00 - 16:10:00 Carstensen